Galsulfase · NAGLAZYME
Protein / enzyme therapeutic
Evidence outlook
Approved: Mucopolysaccharidosis Type VI
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (2)
- Mucopolysaccharidosis VI (MPS VI)
- Long-term enzyme-replacement therapy in confirmed MPS VI (Maroteaux-Lamy)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00067470 NCT00067470 · Mucopolysaccharidosis Type VI Registry: NCT00067470 | 3 | Change From Baseline in 12-minute Walk Test at 24 Weeks (baseline and 24 weeks) | Change From Baseline in 12-minute Walk Test at 24 Weeks (baseline and 24 weeks): rhASB 109 meters (Standard Deviation 154) | Placebo 26 meters (Standard Deviation 122) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.